Search Result

Results for "

insulin secretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IDE (1) IGF-1R (1) Insulin Receptor (33) Acyltransferase (2) Adenylate Cyclase (4) Adrenergic Receptor (2) Akt (3) Aldehyde Dehydrogenase (ALDH) (1) Aldose Reductase (3) Amino acid Transporter (1) AMPK (2) Amylin Receptor (5) Amyloid-β (1) Androgen Receptor (1) Antibiotic (2) AP-1 (1) Apoptosis (31) Arp2/3 Complex (1) Arrestin (3) ATP Synthase (1) Autophagy (11) Bacterial (4) Bcl-2 Family (10) Biochemical Assay Reagents (3) Calcium Channel (7) Carbonic Anhydrase (1) Caspase (4) CDK (1) CGRP Receptor (7) Cholinesterase (ChE) (1) CRFR (2) DAPK (1) Dipeptidyl Peptidase (5) Drug Derivative (1) DYRK (4) Endogenous Metabolite (21) Environmental Pollutants (3) Epigenetic Reader Domain (1) ERK (3) Fatty Acid Synthase (FASN) (2) FBPase (1) Ferroptosis (1) FOXO (2) Free Fatty Acid Receptor (23) Fungal (1) G Protein-coupled Receptor Kinase (GRK) (1) G2A (GPR132) (2) GCGR (16) GHR (1) GHSR (5) GLP Receptor (30) Glucocorticoid Receptor (2) Glucokinase (3) GLUT (2) Glutathione Peroxidase (1) Glycosidase (3) GnRH Receptor (2) GPR119 (7) GSK-3 (1) HMG-CoA Reductase (HMGCR) (2) IFNAR (1) iGluR (1) Influenza Virus (1) Insecticide (1) Interleukin Related (5) IRE1 (1) Isotope-Labeled Compounds (12) JNK (1) LDLR (2) Lipase (1) mAChR (2) Mas-related G-protein-coupled Receptor (MRGPR) (1) MDM-2/p53 (1) MHC (1) Microtubule/Tubulin (2) MMP (1) mRNA (1) mTOR (1) Necroptosis (4) Neuropeptide Y Receptor (4) Neurotensin Receptor (2) NF-κB (14) NKCC (1) Orphan GPCR (1) P2Y Receptor (3) p38 MAPK (13) Parasite (2) PARP (2) PGE synthase (1) Phosphatase (3) Phosphodiesterase (PDE) (2) Phospholipase (1) PKA (8) Potassium Channel (7) PPAR (6) Prostaglandin Receptor (1) PROTAC Linkers (1) Proton Pump (2) PTEN (2) Ras (2) Reactive Oxygen Species (ROS) (8) Reference Standards (16) Ribosomal S6 Kinase (RSK) (1) SLC39 (Zinc Transporter) (1) Somatostatin Receptor (3) Succinate Dehydrogenase (1) Taste Receptor (3) TNF Receptor (3) Trace Amine-associated Receptor (TAAR) (1) TRP Channel (3) VDAC (1) α-synuclein (9)
By Research Areas:	Cancer (37) Cardiovascular Disease (17) Endocrinology (22) Infection (7) Inflammation/Immunology (31) Metabolic Disease (205) Neurological Disease (34)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	mRNA (1) Sweetening Agents (1)

249

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: Insulin Receptor IGF-1R IDE

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0276

GIP, human 2 Publications Verification Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P0055

GLP-1(7-37) 5+ Cited Publications	GLP Receptor	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-142295

GNF2133 1 Publications Verification	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .

HY-P0054A

GLP-1(7-36), amide 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-108611

AACOCF3 4 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

HY-W012241

Dodecanedioic acid	Endogenous Metabolite PROTAC Linkers	Metabolic Disease
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W030796A

Lactisole 3 Publications Verification	Taste Receptor	Metabolic Disease
Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets .

HY-12717

Phentolamine 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Phentolamine is an orally active, selective α1 and α2 Adrenergic receptor antagonist. Phentolamine antagonizes the vasodilatory effect of Cromakalim (HY-110011) on isolated circumflex coronary artery segments in dogs. Phentolamine reduces systemic vascular resistance and increases cardiac output. Phentolamine improves erectile dysfunction. Phentolamine can be used for the research of erectile dysfunction .

HY-125798

2,3-Dehydro-2-deoxy-N-acetylneuraminic acid 4 Publications Verification Neu5Ac2en; DANA	Influenza Virus	Infection
N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid (Neu5Ac2en) is a potent neuraminidase (sialidase) inhibitor. N-acetyl-2,3-dehydro-2-Deoxyneuraminic Acid shows inhibitory activities against human neuraminidase enzymes with IC₅₀s of 143, 43, 61, and 74 μM for NEU1, NEU2, NEU3, and NEU4, respectively. Anti-influenza virus activity .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Insulin Receptor	Metabolic Disease
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-121835

GLP-1R agonist 2	GCGR	Metabolic Disease
GLP-1R agonist 2 (compound 2) is an effective GLP-1R agonist that exerts its activating effect by forming hydrogen bonds with the Tyr42, Cys71, and Ser84 residues of GLP-1R. GLP-1R agonist 2 has the potential for research in metabolic diseases such as type 2 diabetes and obesity .

HY-103192

MDL12330A 5 Publications Verification RMI12330A	Adenylate Cyclase Potassium Channel	Neurological Disease Cancer
MDL12330A (RMI12330A) is an adenylyl cyclases inhibitor. MDL12330A can inhibit K_V channels, increases insulin secretion and Ca ²⁺ levels. MDL12330A accentuates contractions in uterine rings and inhibits cardiac functions. MDL12330A can be used for the research of endocrinology, metabolic and cardiovascular disease .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0276A

GIP, human TFA 2 Publications Verification Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P10959

Macupatide LY3532226	Insulin Receptor	Metabolic Disease
Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes .

HY-117656

ESI-05 4 Publications Verification NSC 116966	Acyltransferase	Neurological Disease Metabolic Disease
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .

HY-P0055A

GLP-1(7-37) acetate 5+ Cited Publications	GLP Receptor	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-142295A

GNF2133 hydrochloride 1 Publications Verification	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .

HY-P0150

Glucagon (19-29), human	GCGR	Neurological Disease
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease Inflammation/Immunology
Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-22306

β-D-Glucose pentaacetate Penta-O-acetyl-β-D-glucopyranose	Others	Metabolic Disease
β-D-Glucose Pentaacetate (Penta-O-acetyl-β-D-glucopyranose) is a glucose derivative, which is mainly used to explore the mechanism of insulin secretion .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-157189

GPR132 antagonist 1 1 Publications Verification	G2A (GPR132)	Metabolic Disease
GPR132 antagonist 1 (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC₅₀ value of 0.075 μM. GPR132 antagonist 1 has promote insulin secretion activity with an EC₅₀ value of 0.7 μM .

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-B1021

Vincamine 1 Publications Verification	Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-164781

KOTX1 1 Publications Verification MBE1	Aldehyde Dehydrogenase (ALDH)	Metabolic Disease
KOTX1 is an orally active and selective ALDH1A3 inhibitor. KOTX1 improves glucose tolerance, insulin secretion and blood sugar levels in diabetic mouse models .

HY-142162

LSN3318839	GCGR	Metabolic Disease
LSN3318839 is an orally active positive modulator of the glucagon-like peptide-1 receptor (GLP-1R). LSN3318839 can increase the secretion of insulin and has the effect of lowering blood sugar .

HY-107651

VU 0365114 1 Publications Verification	mAChR	Metabolic Disease
VU 0365114 is a selective mAChR M₅ positive allosteric modulator, with an EC₅₀ of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells .

HY-P10769

MOTS-c (mouse) 2 Publications Verification	AMPK Apoptosis	Metabolic Disease
MOTS-c (mouse) is a mitochondrial-derived polypeptide that can be used to regulates pancreatic cell function. MOTS-c (mouse) reduces insulin secretion and expression in INS-1E cells, and enhances glucagon secretion and expression in αTC-1 cells. MOTS-c (mouse) decreases the apoptosis in INS-1E and αTC-1. MOTS-c (mouse) counteracts diet-induced obesity and insulin resistance through AMPK activation .

HY-128400

4'-Methoxychalcone	PARP	Metabolic Disease Cancer
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-W030796

Lactisole free acid 3 Publications Verification	Taste Receptor	Metabolic Disease
Lactisole free acid is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole free acid inhibits insulin secretion induced by glucose in mouse islets .

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-143312

V-0219	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 potentiates glucose-dependent insulin secretion. V-0219 improves glucose handling in normal and diabetic rodents. V-0219 can be used for the research of obesity-associated diabetes .

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .

HY-12699

RO5166017 2 Publications Verification	Trace Amine-associated Receptor (TAAR)	Metabolic Disease
RO5166017 is an orally active and species-crosses TAAR1 agonist, with K_i values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively .

HY-P10413

SHBG(141–161)	Androgen Receptor	Metabolic Disease Endocrinology
SHBG 141-161 is a GPRC6A receptor agonist. SHBG 141-161 mimics the action of GPRC6A endogenous agonist uncarboxylated osteocalcin by binding to GPRC6A and promoting downstream signaling to increase testosterone and insulin secretion. SHBG 141-161 also reduces the affinity of GPRC6A to GDP protein by binding to the outer cell domain of GPRC6A thus affecting the dynamics of signal transduction. SHBG 141-161 can be used to study GPRC6A in energy metabolism and endocrine regulation .

HY-143312A

V-0219 hydrochloride	GLP Receptor	Metabolic Disease Inflammation/Immunology
V-0219 hydrochloride is an orally active glucagon-like peptide-1 receptor (GLP-1R) positive allosteric modulator. V-0219 hydrochloride potentiates GLP-1R stimulation, and enhances GLP-1-induced cAMP production and insulin secretion. V-0219 hydrochloride potentiates glucose-dependent insulin secretion. V-0219 hydrochloride improves glucose handling in normal and diabetic rodents. V-0219 hydrochloride can be used for the research of obesity-associated diabetes .

HY-P10959A

Macupatide acetate LY3532226 acetate	Insulin Receptor	Metabolic Disease
Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes .

HY-176040

IXA62	IRE1 Amyloid-β	Neurological Disease Metabolic Disease
IXA62 is an orally active and selective IRE1/XBP1s activator (EC₅₀ = 0.31 μM) that reduces Aβ secretion. IXA62 enhances glucose-stimulated insulin secretion from rat insulinoma cells .

HY-125662A

BMX-001	Reactive Oxygen Species (ROS) Apoptosis	Metabolic Disease
BMX-001, a novel redox-active metalloporphyrin, improves islet function and engraftment in a murine transplant model. BMX-001 reduces apoptosis in human and murine islets. BMX-001 significantly improves static-glucose stimulated insulin secretion (sGSIS) responses in murine islets. BMX-001 can significantly restore euglycemia in murine islet studies in the presence of the MnSOD. BMX-001 reduces the generation of ROS in a murine islet isolation and culture model .

HY-P5074

GRPP (human)	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

HY-107535

AS1269574	GPR119 TRP Channel	Metabolic Disease
AS1269574 is a potent, orally available GPR119 agonist, with an EC₅₀ of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .

HY-P10965

Zovaglutide ZT002	GLP Receptor	Metabolic Disease
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .

HY-143401

Hit 1	IDE	Metabolic Disease
Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC₅₀ of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion .

HY-158584

13-OAHSA 9Z-Octadecenoic acid, 12-carboxy-1-pentyldodecyl ester	Endogenous Metabolite	Metabolic Disease
13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration .

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library

1,113 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 1,113 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-114118

Semaglutide 30+ Cited Publications	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P0276

GIP, human 2 Publications Verification Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P0055

GLP-1(7-37) 5+ Cited Publications	GLP Receptor	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0054A

GLP-1(7-36), amide 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-114118B

Semaglutide acetate 30+ Cited Publications	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118A

Semaglutide TFA 30+ Cited Publications	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-P0276A

GIP, human TFA 2 Publications Verification Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-114118CP

Semaglutide (crude)	GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10959

Macupatide LY3532226	Insulin Receptor	Metabolic Disease
Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes .

HY-P0055A

GLP-1(7-37) acetate 5+ Cited Publications	GLP Receptor	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P10735

GIP (mouse) Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)	Lipase Apoptosis	Metabolic Disease
GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes *insulin* secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .

HY-P0150

Glucagon (19-29), human	GCGR	Neurological Disease
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-109555

Insulin glulisine HMR 1964	Insulin Receptor	Metabolic Disease Inflammation/Immunology
Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P1745

InsB (9-23) insulin B chain (9-23)	MHC Insulin Receptor IFNAR	Inflammation/Immunology
InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes .

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-114118S1

Semaglutide-d8 tetraTFA	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8	Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family	Neurological Disease Metabolic Disease Cancer
Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-P10769

MOTS-c (mouse) 2 Publications Verification	AMPK Apoptosis	Metabolic Disease
MOTS-c (mouse) is a mitochondrial-derived polypeptide that can be used to regulates pancreatic cell function. MOTS-c (mouse) reduces insulin secretion and expression in INS-1E cells, and enhances glucagon secretion and expression in αTC-1 cells. MOTS-c (mouse) decreases the apoptosis in INS-1E and αTC-1. MOTS-c (mouse) counteracts diet-induced obesity and insulin resistance through AMPK activation .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P0014B

Liraglutide TFA Maximum Cited Publications 38 Publications Verification	GLP Receptor	Metabolic Disease
Liraglutide (TFA) is an agonist of glucagon-like peptide 1 receptor (GLP-1). Liraglutide (TFA) can activate GLP-1, leading to the release of insulin in the presence of increased glucose concentration. Liraglutide (TFA) also reduces glucagon secretion in a glucose-dependent manner. Liraglutide (TFA) can be studied in research on type 2 diabetes .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P2632

RAD16-I RADA16	Biochemical Assay Reagents	Neurological Disease
RAD16-I (RADA16) is a non-directed self-assembling peptide hydrogel. Under physiological conditions, RAD16-I spontaneously forms a three-dimensional nanofiber network that mimics the extracellular matrix, and possesses excellent properties such as high water content, biocompatibility and degradability. RAD16-I serves as an ideal scaffold for three-dimensional cell culture. RAD16-I not only maintains cell viability and induces self-organization, but also supports cell adhesion, proliferation, differentiation and insulin secretion, effectively stabilizes islet clusters and promotes directed differentiation of the cardiac lineage. RAD16-I can construct a cell-friendly nano-microenvironment for research related to diseases such as myocardial infarction and diabetes .

HY-P10413

SHBG(141–161)	Androgen Receptor	Metabolic Disease Endocrinology
SHBG 141-161 is a GPRC6A receptor agonist. SHBG 141-161 mimics the action of GPRC6A endogenous agonist uncarboxylated osteocalcin by binding to GPRC6A and promoting downstream signaling to increase testosterone and insulin secretion. SHBG 141-161 also reduces the affinity of GPRC6A to GDP protein by binding to the outer cell domain of GPRC6A thus affecting the dynamics of signal transduction. SHBG 141-161 can be used to study GPRC6A in energy metabolism and endocrine regulation .

HY-P10959A

Macupatide acetate LY3532226 acetate	Insulin Receptor	Metabolic Disease
Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes .

HY-P2541A

GIP (1-30) amide, porcine TFA	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion ^[1][2].

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

HY-P3641A

Kisspeptin 13 TFA	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 TFA is the TFA salt form of Kisspeptin 13 (HY-P3641). Kisspeptin-13 TFA inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 TFA activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 TFA interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 TFA is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P5074

GRPP (human)	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

HY-P2378

Neuromedin U-25 (human)	Endogenous Metabolite	Cardiovascular Disease
Neuromedin U-25 human is the active form of neuromedin U in human. Neuromedin U-25 human inhibits glucose-stimulated insulin secretion, which leads to early-onset obesity. Neuromedin U-25 serves as vasoconstrictor in human vascular beds .

HY-P1427A

Guangxitoxin 1E TFA	Potassium Channel	Neurological Disease
Guangxitoxin 1E TFA is the TFA salt form of Guangxitoxin 1E (HY-P1427). Guangxitoxin 1E TFA is a peptide toxin and a selective inhibitor for voltage-gated potassium channel K_V2.1 and K_V2.2 with IC₅₀ of 1-3 nM. Guangxitoxin 1E TFA enhances glucose-stimulated intracellular calcium ion oscillations and increases insulin secretion in a glucose-dependent manner .

HY-P3019A

Urocortin III (human) TFA	CRFR	Cardiovascular Disease Neurological Disease Metabolic Disease
Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF_2β (K_i = 13.5 nM) and rCRF_2α (K_i = 21.7 nM), while demonstrating negligible affinity for hCRF1 (K_i >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P10965

Zovaglutide ZT002	GLP Receptor	Metabolic Disease
Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .

HY-P10302

GLP-1R/GIPR agonist-1	GLP Receptor Insulin Receptor	Metabolic Disease
GLP-1R/GIPR AgonIST-1 is a double-receptor agonist for GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin releasing peptide). GLP-1R/GIPR agonist-1 lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH) .

HY-P3641

Kisspeptin 13	GnRH Receptor	Neurological Disease Metabolic Disease
Kisspeptin 13 inhibits glucose-induced insulin secretion with an IC₅₀ of 1.2 nM. Kisspeptin 13 activates the hypothalamic-pituitary-adrenal (HPA) axis, causes hyperthermia, motor behavior and anxiety in rats. Kisspeptin 13 interacts with α2-adrenergic and 5-HT2 serotonin receptors, exhibits antidepressant efficacy. Kisspeptin 13 is an activator for GPR54 and GnRH receptor, which enhances memory and can be used in Alzheimer's disease research .

HY-P11043

GEP44	GLP Receptor Neuropeptide Y Receptor Arrestin	Metabolic Disease
GEP44 is a peptide biased triple agonist targeting Glucagon-like peptide 1 receptor (GLP-1R), neuropeptide Y1 Receptor (Y1-R), and neuropeptide Y2 Receptor (Y2-R). GEP44 induces Y1-R antagonist-controlled, GLP-1R-dependent stimulation of insulin secretion in both rat and human pancreatic islets by counteracting effects of Y1-R and GLP-1R agonism. GEP44 promotes insulin-independent Y1-R-mediated glucose uptake in muscle tissue and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 can be used for obesity and type 2 diabetes mellitus research .

HY-P2534

C-Peptide 2, rat	Insulin Receptor	Metabolic Disease
C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .

HY-P1257

Xenin-8	Insulin Receptor Neurotensin Receptor	Metabolic Disease
Xenin-8, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC₅₀=0.16 nM) .

HY-103545

GIP (1-39) Gastric inhibitory peptide (1-39) (porcine)	Insulin Receptor	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992159

Anti-ZnT8 Antibody (mAb43)	SLC39 (Zinc Transporter)	Metabolic Disease Inflammation/Immunology
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0755

Rhoifolin	Rhus succedanea Flavonoids Classification of Application Fields Flavones Plants Disease Research Fields Endocrinology Anacardiaceae Cancer	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

HY-W012241

Dodecanedioic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite PROTAC Linkers
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W040127

Peonidin 3-O-glucoside chloride 1 Publications Verification	Anthocyans Flavonoids Classification of Application Fields Vitis vinifera cv. Zalema Metabolic Disease Plants Vitaceae Disease Research Fields Source Classification	Insulin Receptor
Peonidin 3-O-glucoside chloride is an agonist of the free fatty acid receptor FFAR1 and Glucokinase. Peonidin 3-O-glucoside chloride enhances insulin secretion of pancreatic beta cells and increases glucose uptake by liver cells. Peonidin 3-O-glucoside chloride activates FFAR1, promotes the phosphorylation of related proteins in the insulin secretion pathway, and increases the expression of FFAR1. In liver cells, Peonidin 3-O-glucoside chloride activates GK and regulates proteins associated with carbohydrate metabolism. Peonidin 3-O-glucoside chloride can be used in diabetes research .

HY-N2118

Bilobetin 2 Publications Verification	Flavonoids Ginkgoaceae Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Biflavones Ginkgo biloba Disease Research Fields Source Classification	PPAR PKA Akt p38 MAPK ERK
Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-W016715

L-Cysteine hydrochloride hydrate Maximum Cited Publications 12 Publications Verification	Classification of Application Fields Metabolic Disease Amino acids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB Insulin Receptor
L-Cysteine hydrochloride hydrate is an orally active and essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate regulates CBS/H2S pathway, inhibits NF-κB activation and *insulin* and ghrelin secretion. L-Cysteine hydrochloride hydrate reduces blood sugar, vascular inflammation markers and appetite. L-Cysteine hydrochloride hydrate induces kidney damage. L-Cysteine hydrochloride hydrate can be used in the study of neurological diseases and diabetes .

HY-135897

Urolithin C 5 Publications Verification	Classification of Application Fields Phenols Polyphenols Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of **insulin secretion. Urolithin C is a L-type Ca ²⁺ channel opener and enhances Ca ²⁺ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS)** formation .

HY-N3021

D-chiro-Inositol	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0466

Rebaudioside A	Structural Classification Classification of Application Fields Plants Compositae Endogenous metabolite Sweeteners Food Research Trifolium hybridum L. Terpenoids Other Diseases Diterpenoids Disease Research Fields Source Classification	Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR
Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC₅₀ value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity .

HY-N15721

Tryptophan-cholic acid Trp-CA	Triterpenes Structural Classification Terpenoids Endogenous metabolite Source Classification	Orphan GPCR GLP Receptor
Tryptophan-cholic acid (Trp-CA) is a microbial amino acid-conjugated bile acid that acts as an endogenous ligand and agonist (EC₅₀=9.6 μM) for the orphan G protein-coupled receptor (GPCR) MRGPRE (Mas-related G protein-coupled receptor family member E). Tryptophan-cholic acid is orally effective but has poor oral absorption and does not cross the blood-brain barrier. Tryptophan-cholic acid promotes the secretion of glucagon-like peptide GLP-1, thereby improving glucose tolerance in diabetic mice. Tryptophan-cholic acid improves glucose tolerance, promotes insulin secretion, and alleviates high-fat diet-induced hepatic steatosis without causing pruritus side effects. Tryptophan-cholic acid is primarily used in research on type 2 diabetes (T2D) .

HY-22306

β-D-Glucose pentaacetate Penta-O-acetyl-β-D-glucopyranose	Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Saccharides Source Classification	Others
β-D-Glucose Pentaacetate (Penta-O-acetyl-β-D-glucopyranose) is a glucose derivative, which is mainly used to explore the mechanism of insulin secretion .

HY-B1021

Vincamine 1 Publications Verification	Apocynaceae Cardiovascular Disease Alkaloids Classification of Application Fields Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Free Fatty Acid Receptor
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-128400

4'-Methoxychalcone	Flavonoids Chalcones Classification of Application Fields Piperaceae Plants Disease Research Fields Piper nigrum Linn. Cancer Source Classification	PARP
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-120657

9-PAHSA	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Endogenous metabolite Disease Research Fields Source Classification	CGRP Receptor NF-κB
9-PAHSA is an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

HY-N6005

Methyl caffeate	Infection Structural Classification Classification of Application Fields Simple Phenylpropanols Phenols Polyphenols Solanum torvum Swartz Phenylpropanoids Solanaceae Plants Disease Research Fields Source Classification	Bacterial Fungal Apoptosis Bcl-2 Family
Methyl caffeate is a phenylpropanoid, antibacterial agent, and Apoptosis-inducing agent. Methyl caffeate can be isolated from the flowers of peach Prunus persica (L.). Methyl caffeate upregulates the expression of pro-apoptotic proteins Bid, Bax and p53, and downregulates the expression of anti-apoptotic protein BCL-2. Methyl caffeate downregulates SASP factors. Methyl caffeate enhances glucose-stimulated insulin secretion. Methyl caffeate inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, fungi, and Mycobacterium tuberculosis strains. Methyl caffeate can be used in studies related to breast cancer, type 2 diabetes, and tuberculosis .

HY-N9536

Cinnamtannin A2	Flavanonols Flavonoids Cinnamomum cassia (L.) D. Don Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Lauraceae Biflavones Disease Research Fields Source Classification	GLP Receptor
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect .

HY-N2452

Cochinchinenin C	other families Classification of Application Fields Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	GLP Receptor
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .

HY-W012241R

Dodecanedioic acid (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-N3021R

D-chiro-Inositol (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0755R

Rhoifolin (Standard)	Structural Classification Rhus succedanea Flavonoids Flavones Plants Anacardiaceae	Reference Standards Insulin Receptor GLUT NF-κB p38 MAPK Autophagy
Rhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

HY-N0466R

Rebaudioside A (Standard)	Structural Classification Trifolium hybridum L. Terpenoids Diterpenoids Plants Compositae Endogenous metabolite Source Classification	Reference Standards Glycosidase HMG-CoA Reductase (HMGCR) Fatty Acid Synthase (FASN) LDLR
Rebaudioside A (Standard) is the analytical standard of Rebaudioside A. This product is intended for research and analytical applications. Rebaudioside A is an orally effective steviol glycoside with high sweetness. Rebaudioside A acts as an inhibitor of α-glucosidase with an IC₅₀ value of 35.01 μg/mL. Rebaudioside A increases the ATP/ADP ratio in β cells in a glucose-dependent manner, thereby inhibiting KATP channels, leading to membrane depolarization, calcium influx, and ultimately stimulating insulin secretion. Rebaudioside A activates the SREBP signaling pathway by inhibiting HMGCR, the rate-limiting enzyme in cholesterol synthesis, resulting in increased expression of LDLR on the cell surface, thus promoting the uptake of LDL-C in the blood. Rebaudioside A can be used for studies on blood glucose and lipid regulation as well as anti-obesity.

HY-B1021R

Vincamine (Standard)	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	Reference Standards Free Fatty Acid Receptor
Vincamine (Standard) is the analytical standard of Vincamine. This product is intended for research and analytical applications. Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-128400R

4'-Methoxychalcone (Standard)	Structural Classification Chalcones Flavonoids Piperaceae Plants Piper nigrum Linn. Source Classification	PARP Reference Standards
4'-Methoxychalcone (Standard) is the analytical standard of 4'-Methoxychalcone. This product is intended for research and analytical applications. 4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-N2118R

Bilobetin (Standard)	Structural Classification Flavonoids Ginkgoaceae Phenols Polyphenols Plants Biflavones Ginkgo biloba Source Classification	Reference Standards PPAR PKA Akt p38 MAPK ERK
Bilobetin (Standard) is the analytical standard of Bilobetin. This product is intended for research and analytical applications. Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .

HY-135897R

Urolithin C (Standard)	Phenols Polyphenols Endogenous metabolite Source Classification	Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Endogenous Metabolite
Urolithin C (Standard) is the analytical standard of Urolithin C. This product is intended for research and analytical applications. Urolithin C, a gut-microbial metabolite of Ellagic acid, is a glucose-dependent activator of insulin secretion. Urolithin C is a L-type Ca2+ channel opener and enhances Ca2+ influx. Urolithin C induces cell apoptosis through a mitochondria-mediated pathway and also stimulates reactive oxygen species (ROS) formation .

HY-113513

5-HEPE	Microorganisms Source Classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

HY-120657R

9-PAHSA (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards CGRP Receptor NF-κB
Flumethrin (Standard) is the analytical standard of Flumethrin. This product is intended for research and analytical applications. 9-PAHSA is an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

HY-N18033

Glyceollin III	Structural Classification Monophenols Leguminosae Glycine max (L.) merr Phenols Plants Source Classification	Insulin Receptor GLP Receptor
Glyceollin III is a glyceollin found in soybeans. Glyceollin III enhances insulin-stimulated glucose uptake and increases glucagon-like peptide-1 (GLP-1) secretion. Glyceollin III can be used for the research of type 2 diabetes .

HY-N19830

Guavenoic acid	Triterpenes Structural Classification Terpenoids Psidium guajava Linn. Myrtaceae Plants Source Classification	Reactive Oxygen Species (ROS) Apoptosis
Guavenoic acid is a triterpenoid compound that can be isolated from fresh leaves of Psidium guajava. Guavenoic acid protects cells in cellular oxidative damage models, inhibits intracellular ROS production, and suppresses cell apoptosis. Guavenoic acid significantly enhances cellular proliferation, promotes insulin synthesis and secretion, and upregulates the messenger RNA expression of insulin gene, PDX-1 and MafA. Guavenoic acid can be used in the research of diseases such as pancreatic islet β-cell tumors .

HY-N17326

Ilekudinol B	Weigela subsessilis (Nakai) L.H.Bailey Structural Classification Caprifoliaceae Terpenoids Plants Pentacyclic Triterpenoids Source Classification	Acyltransferase Phosphatase Interleukin Related
Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC₅₀ of 5.3 μM and a K_i of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC₅₀ of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases .

HY-N19401

Vescalagin	Structural Classification Phenols Polyphenols Myrciaria dubia (Kunth) McVaugh Myrtaceae Plants Source Classification	Cholinesterase (ChE) Carbonic Anhydrase Glycosidase JNK p38 MAPK
Vescalagin is a hexahydroxyphenol. Vescalagin is isolable from Camu-camu (Myrciaria dubia) and immature wax apple fruits. Vescalagin exhibits inhibitory activity against a variety of enzymes, with a K_i value of 5.87 nM against AChE, 3.89 nM against BChE, 11.75 nM against hCA I, 16.23 nM against hCA II, and 16.08 nM against α-glucosidase. Vescalagin inhibits hCA I, hCA II and α-glucosidase in a non-competitive manner. Vescalagin downregulates JNK/p38 MAPK to protect pancreatic β-cells and improve insulin secretion in methylglyoxal-treated rats. Vescalagin reduces hyperglycemia and hypertriglyceridemia in rats fed a high-fructose diet. Vescalagin possesses anti-inflammatory and antioxidant properties .

HY-N17816

Tambulin	Structural Classification Flavonoids Flavones Rutaceae Plants Zanthoxylum armatum DC. Source Classification	Apoptosis Reactive Oxygen Species (ROS) α-synuclein Succinate Dehydrogenase Bcl-2 Family Caspase
Tambulin is an orally active flavonol compound found in Zanthoxylum armatum. Tambulin can inhibit cell proliferation, induce apoptosis and inhibit ROS production. Tambulin upregulates cleaved caspase-3, cleaved caspase-9, and Bax, downregulates Bcl-2 levels. Tambulin can stimulate glucose-dependent insulin secretion and induce endothelium-independent vasorelaxation. Tambulin binds to succinate dehydrogenase (SDH) (Ki = 11.02 μM) and shows significant ferric reducing power. Tambulin can enhances oxidative stress resistance, reduces, lipofuscin deposits, lipid levels, α-synuclein levels, improves locomotary behavior, and dopamine levels in in age-synchronized L1 hermaphrodite Caenorhabditis elegans models of ageing and Parkinson's disease. Tambulin can be used for the researches of Parkinson's disease, lung squamous cell carcinoma, and diabetes .

Cat. No.	Product Name	Chemical Structure

HY-114118S3

Semaglutide-13C6,15N TFA

Semaglutide- ¹³C₆, ¹⁵N TFA is the ¹³C- and ¹⁵N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S1

Semaglutide-d8 tetraTFA

Semaglutide-d₈ tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-114118S

Semaglutide-d8

Semaglutide-d₈ is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .

HY-W012241S1

Dodecanedioic acid-d4

Dodecanedioic acid-d₄ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W770410

9-PAHSA-13C4

9-PAHSA- ¹³C₄ is ¹³C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

HY-W724355

Denatonium benzoate-d5

Denatonium benzoate-d₅ (THS-839-d₅) is the deuterium labeled Denatonium benzoate (HY-B1146). Denatonium benzoate (THS-839) is known as the most bitter compound and is commonly used as a deterrent (bittering agent) to activate different types of bitter taste receptors (TAS2Rs) with oral activity. Denatonium benzoate can enhance insulin secretion, has anti-inflammatory effects, and promotes allergy susceptibility .

HY-120657S

9-PAHSA-d4

9-PAHSA-d₄ is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

HY-W012241S

Dodecanedioic acid-d20

Dodecanedioic acid-d₂₀ is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W777762

Dodecanedioic Acid-13C12

Dodecanedioic Acid- ¹³C₁2 is the ¹³C-labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .

HY-W014839S

Cyclamic acid-d11 sodium

Cyclamic acid-d₁₁ (Sodium cyclamate-d₁₁) sodiumis deuterium labeled Cyclamic acid (sodium). Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

HY-W014839S1

Cyclamic acid-d4 sodium

Cyclamic acid-d₄ (Sodium cyclamate-d₄) sodium is the deuterium labeled Cyclamic acid sodium (HY-W014839). Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

HY-144026S

9-PAHSA-d9

9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

HY-120657S1

9-PAHSA-d31

9-PAHSA-d₃₁ is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC₅₀=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease .

Cat. No.	Product Name		Classification

HY-115643

AZ13581837		Alkynes
AZ13581837 is a GPR120 agonist with oral effectiveness, human EC₅₀ values of 5.2 nM, and mouse EC₅₀ of 4.3 nM. AZ13581837 signals through Gαq, Gαs, and β-arrestin pathways, reduces cAMP production, stimulates GLP-1 secretion, induces glucose lowering, and increases insulin secretion. AZ13581837 can be used for the research of type 2 diabetes .

Cat. No.	Product Name		Classification

HY-W014839

Cyclamic acid sodium Sodium cyclamate; Cyclohexylsulfamic acid sodium		Sweetening Agents
Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine .

HY-174773

Human BTC mRNA		mRNA
Human BTC mRNA encodes the human betacellulin (BTC) protein, a member of the epidermal growth factor family. BTC promotes pancreatic cell proliferation and insulin secretion, as well as retinal vascular permeability.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks